Merck & Co has filed Keytruda in bladder cancer in the US, setting the scene for a battle with rivals Roche and Bristol-Myers Squibb. Bristol-Myers Squibb’s rival immunotherapy Opdivo (nivolumab ...

There could be new hope on for kidney cancer patients. Researchers announced early results of an anti-tumor vaccine for patients with stage 3 or 4 kidney cancer, who face high recurrence risk.

Results from a small retrospective analysis of patients with upper tract urothelial carcinoma lesions were shared at the 2025 ASCO Genitourinary Cancers Symposium.

This approach aims to improve treatment for patients with this highly aggressive and treatment-resistant type of breast ...

Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil ...

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD outside of Canada and the US) ...

Boston-based Bicara launched in 2021 and is a subsidiary of Indian pharma company Biocon, which provided its seed funding. Bicara is also studying ficerafusp alfa, its lead candidate, in anal cancer ...

Keytruda and Lenvima with chemotherapy improved progression ... Anti-PD-1 therapy: a type of immunotherapy that uses blocking antibodies to treat cancer. Blinded independent central review (BICR): ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Market OverviewThe Global Breast Cancer Therapeutics Market  remains one of the most prevalent forms of cancer worldwide, ...